Ocena postępowania diagnostycznego i terapeutycznego w ...

159. Kapusta M, Dzierzanowska D, Dunin-Wąsowicz D, Detection of cytomegalovirus in infant
cerebrospinal fluid by conventional PCR, nested PCR and PCR-Digene, Acta Microbiol. Pol.
2001; 50: 263-74.
160. Gennery AR, Cant AJ, Jeggo PJ. Immunodeficiency associated with DNA repair defects. Clin
Exp Immunol. 2000; 212: 1-7
161. Lim MS, Elenitoba-Johnson KS. The molecular pathology of primary immunodeficiencies. J
Mol Diagn. 2004; 6: 59-83.
162. Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD) - its clinical
presentation and molecular basis. DNA Repair. 2004; 3: 1219-25.
163. Boffetta P, Chrzanowska KH. Epidemiologic perspective studies of NBS and lymphoma.
International Workshop on Nijmegen Breakage Syndrome, 8-11 June 2000, Częstochowa,
Polska.
164. Kruger L, Demuth D, Neitzel H i wsp. Cancer incidence and Nijmegen breakage syndrome is
modulated by the amount of a variant NBS protein. Carcinogenesis 2007; 28: 107-11.
165. Morell D, Cromartie E i Swift M. Mortality and cancer incidence in 263 patients with ataxia
telangiectasia. J Natl Cancer Inst. 1986; 77: 89-92.
166. Grenzebach J, Schrappe M, Ludwig W i wsp. Favorable outcome for children and adolescents
with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local
radiotherapy. Ann Hematol. 2001; 80: B73-76
167. Mora J , Filippa D, Qin J, Wallner N. Lymphoblastic lymphoma of childhood and the LSA 2 -L 2
protocol. The 30-year experience at Memorial Sloan-Kettering Cancer Center. Cancer. 2003;
98: 1283-91.
168. Miles R, Raphael M, McCarthy K i wsp. Pediatric Diffuse Large B-cell Lymphoma
demonstrates a high Proliferation Index, frequent c-Myc protein expression, and a high
incidence of Germinal Center subtype: Report of the French- American-British (FAB)
International Study Group. Pediatr Blood Cancer. 2008; 51: 369–74.
169. Gładkowska-Dura M, Chrzanowska KH, Dura W. Malignant lymphoma in Nijmegen
syndrome. Ann Pediatr Pathol. 2000; 4: 39-46.
170. Stankovic T, Kidd AMJ, Sutcliffe A i wsp. ATM mutations and phenotypes in ataxiatelangiectasia
families in the British Isles: expression of mutant ATM and the risk of
leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998; 62: 334-45.
171. Oschlies I, Salaverria I, Mahn F, i wsp. Pediatric follicular lymphoma – a clinico-pathological
study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma -
Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials. Haematologica. 2010; 95: 253-59.
172. Gładkowska-Dura M, DzierŜanowska-Fangrat K, Dura W i wsp. Unique morphological
spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency
of consecutive lymphoma formation. J Pathol. 2008; 216: 337–44.
173. Szczepaniak-Kubat A, Trelińska J, Zalewska-Szewczyk B i wsp. Inwazyjne zakaŜenie
grzybicze w przebiegu chemioterapii u pacjentów z zespołem Nijmegen - prezentacja dwóch
przypadków. Przeg Pediatr. 2007; 37: 331-334
174. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxiateleangiectasia.
Med Pediatr Oncol. 1998; 31: 491-97.
175. Rossi G, Zecca M, Marchi A i wsp. Modified CHOP-chemotherapy plus rituximab for diffuse
large B-cell lymphoma complicating ataxia-teleangiectasia. Br J Haematol. 2003; 120: 369-71.
176. Rogers P, Plowman P, Harris S, Arlett C. Four radiation hypersensitivity cases and their
implications for clinical radiotherapy. Radiother Oncol. 2000; 57: 143-54.
177. Olsen JH. Cancer in patients with atxia-teleangiectasia and their relatives in the Nordic
countries. J Natl Cancer Inst. 2001; 93: 121-27.
178. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002; 23:
687-96.
179. Stumm M, Neubauer S, Keindorff S i wsp. High frequency of spontaneous translocations
revealed by FISH in cells from patients with the cancer-prone syndromes ataxia telangiectasia
and Nijmegen breakage syndrome. Cytogenet Cell Genet. 2001; 92: 186-91.
180. Kirsch IR, Lista F. Lymphocyte-specific genomic instability and risk of lymphoid malignancy.
Semin Immunol. 1997; 9: 207-15.
144